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Abstract  
            The aim of this research work is to study the prevalence of 
human cytomegalovirus (HCMV) infection in renal transplant and 
haemodialysis patients in Khartoum State and to improve the 
diagnosis of HCMV through the introduction of the polymerase chin 
reaction (PCR). 
        Blood samples were collected randomly from 52 renal transplant 
patients and 48 haemodialysis patients. 
           The collected samples were investigated with the Enzyme 
linked immunosorbent assay (ELISA) and indirect 
immunofluorescence test (IFT) to detect the HCMV IgG antibodies 
and ELISA test to detect HCMV IgM antibodies.  
DNA samples were extracted and the PCR was conducted and 
the PCR amplified products were detected by the gel electrophoresis. 
Renal transplant screening of HCMV IgG revealed that 98% of 
patients have IgG for HCMV antibodies and only 6% have IgM 
antibodies. In haemodialysis patients 95% showed the presence of IgG 
antibodies to HCMV and zero% revealed the presence of IgM 
antibodies.            
The prevalence of HCMV IgG antibodies was also determined 
using IFT in renal transplant and haemodialysis patients with 98%, 
89.3% seropositivity, respectively.                                                                                
Inoculation the ELISA detected 97% of the HCMV antibodies 
in the samples while the IFT detected 95% of the samples. Both 
assays were sensitive for detection of HCMV IgG antibodies. The 
PCR was found to be rapid and sensitive and it detected viral genome 
in 7.5% of the serum samples. 
vii 
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CHAPTER ONE 
INTRODUCTION 
Human cytomegalovirus (HCMV) is a member of the genus 
Herpes virus and belongs to the family Herpesviridae. As with all 
members of the family, the virus has the ability to persist in the host in 
a latent state after primary infection (Emery, 2001). It is a ubiquitous 
virus, the seroprevalence of which varies between 30 to 100 % in 
different countries. Acquisition of the virus in the general population 
mainly occurs early in life. Transmission of the virus can occur 
vertically or horizontally via direct contact with infectious body fluids 
or blood. The virus can also be transmitted by blood products or 
transplanted organs. After the primary infection, the virus will remain 
in a latent state in the host life-long but may reactivate later. Although 
rarely pathogenic in immunocomptent individuals, the virus posses a 
significant health threat to immunocompromised individuals and is a 
significant cause of morbidity and mortality especially in organ 
allograft and bone marrow transplant patients (Partel et al., 1992; 
Benz, 2000).  
In the immunocompetent individual, the virus and host exist in a 
symbiotic equilibrium, such that disease manifestations are rarely 
encountered. However, when the host immune system is 
compromised, either through infection—for example, by human 
immunodeficiency virus (HIV), immaturity (neonate), or through 
iatrogenic means following organ transplantation, the virus is able to 
exert its full pathogenic potential (Emery, 2001). In 
immunocompromised patients, severe HCMV infections may occur. 
HCMV is a significant pathogen in organ transplanted patients 
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causing symptomatic infections and end-organ disease. Many risk 
factors for the development of symptomatic infection have been 
suggested. Viral load has been shown to be a major factor in the 
development of HCMV disease. In most developed countries Human 
cytomegalovirus (HCMV), seroprevalence steadily increases after 
infancy, and 10-20% of children are usually infected before puberty. 
In adults the prevalence of antibodies ranges from 40-100%. Infection 
with HCMV being more common in developing countries and in areas 
with low socioeconomic condition which is predominantly related to 
closeness of contacts within these population (De Jong et al., 1998).      
 HCMV causes 8% of mononucleosis syndromes (Britt and 
Alford, 1996) atherosclerotic coronagy artery, congenital infections 
(Boppana et al., 1992), and clinical syndromes associated with HCMV 
infections in AIDS patients (Britt and Alford, 1996). Prepheral blood 
mononuclear cells expressing CD13+ antigen as monocytes and 
certain CD8+ lymphocytes are permissive to HCMV (Soderberg et al., 
1993). Monocytes have been identified as the major site of latency of 
HCMV in peripheral blood of healthy carriers and are more likely to 
transform latent infection. Allogeneic stimulation of peripheral blood 
mononuclear cells by T cells provides an immunologic stimulus that 
facilitates reactivation of latent HCMV (Soderbergy et al., 1997). 
Thus HCMV may be reactivated from latently infected cells after 
blood transfusion. In general; transfusion of unscreened cellular 
components leads to TT- HCMV incidence of approximately 30% in 
seronegative recipients (Hillyer et al., 1994). 
The first surveillance of HCMV infection in Sudan was done in 
2004, in blood donors and antenatal women (Eldowma, 2004). And 
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the second surveillance was done in 2006, in candidate recipients, 
kidney candidate donors and blood donors (Bushera, 2006). Diagnosis 
of HCMV was made by clinical symptoms, laboratory conformation 
was achieved by serological methods Enzyme linked Immunosorbent 
assay (ELISA) &Immunofluorescen test (IFT). The symptoms of 
HCMV are confused with Epstein –Barr virus (EBV), and this may 
lead to difficulties in diagnosis. The serological methods used are 
useful to detect past exposure (IgG) but not useful for early diagnosis 
of acute infection, because failure to detect IgM in the presence of 
viruria.  
Objectives: 
1. Investigate the prevalence of HCMV lgG and IgM 
antibodies among renal transplant recipients and 
Haemodialysis patients. 
2. Improving laboratory diagnosis of CMV in renal transplant 
and Haemodialysis patients by PCR and IFT in the Sudan.   
3. Comparison between sensitivity of molecular techniques and 
serologic techniques. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1. Definition 
Cytomegalovirus (CMV) infections are common and usually 
asymptomatic infection; however, the incidence and spectrum of 
disease in newborns and in immunocompromised hosts establish this 
virus as an important human pathogen. CMV infection can be 
classified as those acquired befor birth (congenital), at the time of 
delivery (prenatal), or later in life (postnatal) (Hodinka et al., 1991).    
2.2. History of Cytomegalovirus 
Cytomegalovirus (CMV) was first isolated from the salivary 
gland and kidney of two dying infant with cytomegalic inclusion 
bodies and reported in 1956 (Smith, 1956). Two other laboratories 
isolated CMV at approximately the same time. Thus CMV was 
initially called "Salivary gland virus" or" “Salivary gland inclusion 
disease virus”. 
In 1960, Weller et al (1957) proposed the use of the term 
cytomegalovirus. Klemola and Kaarianinen first described CMV 
mononucleosis CMV was first isolated in renal transplant recipients in 
1956. 
2.3. The Genus Cytomegalovirus      
Human cytomegalovirus (HCMV) is member of the 
Betaherpesvirinae subfamily, of the family Herpesviridae. Its 
replication cycle is significantly longer and infected cells typically are 
greatly enlarged and multinucleated thus the name cytomegalo 
(William et al., 2001).  
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Human cytomegalovirus (HCMV) is vernacular name of human 
herpes virus 5 highly host-specific virus of the herpesviridae family. 
HCMV is the largest virus in the family and is morphologically 
indistinguishable from other human herpesviruses. HCMV, like all 
herpesviruses, causes latency and reactivation in the host. Although 
HCMV has been shown to infect a broad spectrum of cells in vivo 
(Sinzger et al., 1995).  
2.3.1. Structure and biology of human cytomegalovirus 
Human cytomegalovirus is a herpesvirus, with enveloped 
virion, about 150 nm in diameter, and consists of an icosahedral 
nucleocapsid about 100 nm in diameter, composed of 162 hollow 
capsomers -150 hexamers and 12 pentamers. The viral genome is 
wrapped around a fibrous spool –like core, which has the shape of a 
torus and appears to be suspended by fibrils that are anchored to the 
inner side of the surrounding capsid and passs through the hol of the 
torus (Murphy et al., 1999). The genome of CMV is also characterized 
by linear DNA molecules ranging in size from 200- 248 kbp. This is 
significantly larger than those of the other a herpesvirus.  Human 
cytomegalovirus genome also exhibits pattern of terminal and inverted 
repeats that vary in size depending on the virus  strain and passage 
history (knipe et al ., 2001). Surrounding the capsid is a layer of 
globular material, known as the tegument which is enclosed by 
atypical lipoprotein envelope with numerous small glycoprotein 
peplomers at least 25 proteins of which are phosphorylated and also 
several transcripational transactivator protein have also been localized 
in the tegument layer between the virion capsid and envelope (knipe et 
al ., 2001 ) (Fig .1). 
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2.3.2. Classification of human cytomegalovirus 
The family herpesviridae is divided into four subfamilies: 
Alphaherpesvirinae, Betaherpesvirinae, Gammaherpesvirinae, and 
Unnamed subfamily. This division was originally based on biological 
properties, but in general it has accorded well with subsequent 
molecular characterization, including nucleotide sequence and 
phylogenic analyses (Murphy et al., 1999). The same study group 
classified a number of herpesvirus into genera based on DNA 
sequence homology. The similarities in genome sequence arrangement 
and relatedness of important viral protein demonstratable by 
immunological methods (Knipe et al., 2001). 
Subfamily Alphaherpesvirinae, these viruses have a relatively 
rapid, cytocidal growth cycle the prototypic viruses of the genra of 
this subfamily is human herpesvirus I (herpes Simplex virus I: genus 
simplexvirus) and human herpesvirus III (Varicella-zostervirus; genus 
Varicellavirus). Gallid herpesvirus I (infectious laryngotracheitis 
virus) and marek's disease virus.  
Subfamily Betaherpesvirinae these viruses have a relatively slow 
replication cycle. The protype of the subfamily is human herpesvirus 
VI (human cytomegalovirus). Subfamily Gammaherpesvirinae, these 
viruses replicate in mucosal epithelium where they also establish 
latent infection and this subfamily comprises the herpesvirses that are 
lymphotropic. The prototype is human herpesvirus - V (Epstein-
Barrvirus; genus lympocrytovirus). Unnamed subfamily, at present 
this subfamily comprises only cannel catfish herpes viruses (William 
et al., 2001; Murphy et al., 1999). 
 
 
 ٧
2.3.3. Human cytomegalovirus replication 
Human cytomegalovirus replication in vitro is relatively slow 
and frequently cultures of clinical specimen need to be maintained for 
many weeks before characteristic cytopathic effects are observed. 
However, until recently, the relevance of these observations to 
replication of CMV in vivo was unclear. The major reservoir of CMV 
in the laten infection is CD14 positive monocytes cells. The prolonged 
allogenic stimulation of these cells from healthy seropositive people 
can lead to the reactivation of virus   (Soderberg et al., 1997) in 
contrast, during an active multiple cell types are infected, although the 
predominant cell types appear to be endothelial cells, neutrophils, and 
lymphocytes. During an active CMV infection, the doubling time of 
CMV is approximately one day; thus, CMV replication occurs 
dynamically in human host, and contrasts with the results obtained 
from in vitro propagation (Emery et al., 1999). 
       HCMV exhibits a restricted host range in cell culture. Although in 
vitro the most commonly used cells are primary differentiated human 
fibroblasts derived from skin or lung, HCMV can also replicate in 
other cell types including endothelial and epithelial cells, smooth 
muscle cells and leukocytes (Pass, 2001). After the attachment of the 
virus to the cell surface, fusion of the virion envelope and the cell 
membrane occurs (Mocarski and Courcelle, 2001). Epidermal growth 
factor receptor has recently been suggested to serve as a receptor for 
HCMV (Wang et al., 2003). The virus capsid is rapidly transported to 
the cell nucleus and, after the proteolysis of the capsid proteins; the 
viral DNA is released into the nucleus. Viral gene expression in 
productive replication occurs in a temporally ordered cascade 
(Mocarski and Courcelle, 2001; Sinclair, 2000). Immediate-early (IE) 
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gene expression is first activated followed by early and late gene 
expression which ultimately leads to virus assembly and release from 
the infected cells. The most abundantly expressed IE genes are 
transcribed from the major IE (MIE) locus, located in the UL region. 
The IE proteins are transactivators of gene expression and play an 
important role in controlling both viral and cellular gene expression. 
The expression of IE proteins is also crucial for the next step of the 
temporal cascade, correct expression of early genes. This is followed 
by the expression of late genes. The early (E) proteins are involved in 
the replication of the viral DNA, whereas late (L) gene expression 
provides the structural proteins/glycoprotein of the viral capsid, 
tegument and envelope. DNA replication, formation of capsids and 
packaging of viral DNA occur in the nucleus. Subsequently, 
nucleocapsids acquire a primary envelopment by budding at the 
nuclear membrane. They further mature through a de-envelopment/re-
envelopment process in the cytoplasm before leaving the cell via an 
exocytic-like pathway (Mettenleiter, 2002; Mocarski and Courcelle, 
2001). The whole replication cycle of human CMV is slow, requiring 
approximately 48-72 hours. The cytopathic effect in response to 
HCMV is characteristically cell enlargement with intranuclear 
inclusions.   
2.3.4. Genome structure 
The genome of characterized CMV is all linear DNA molecule 
ranging in size from 200 to 240 kbp encoded more than 200 proteins. 
This is significantly larger than those of other herpesviruses. Human 
cytomegalovirus genome also exhibits a pattern of terminal and 
inverted repeats that vary in size depending on the virus strain and 
passage history. 
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The human CMV genome has two unique components designated 
unique larger region (UL) and unique short region (Us). Flanked by 
inverted repeats b (TRL / IRL) and c (IRS / TRS) (Figure. 2). A 
directly repeated sequence is found at the genome termini and also 
present in inverted orientation at the L-S junction. The arrangement of 
a sequence promotes genome inversion. The sequence carries Cis- 
signals called pac-1 and pac-2 for cleavage and Packaging of viral 
genome. The human CMV genome is G +C rich and contains a 
significant number of direct and inverted repeats (Murphy et al., 
1999). The regions show an extremely high density closely splaced 
inverted and direct repeats. Human CMV generates defective viruses 
carrying DNA molecules that are shorter than the genome length. The 
novel restriction fragments are found in the defective CMV DNA, 
suggesting that specific deletions or rearrangement occur relative to 
standard viral (Knipe et al., 200l). 
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Figure 1. Schematic diagram of cytomegalovirus (CMV). The CMV 
virus shows a similar composition to all human herpes virus. 
 
 
        
 
Figure 2. Simplified structure of the CMV genome 
(UL = unique larger region, US = unique short region, TRL and TRS 
= terminal repeat sequence, IRL and IRS = inverted repeat sequence).  
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2.4.1. Epidemiology of HCMV          
Cytomegalovirus is endemic in all parts of the world and occurs 
all over the year, with non seasonal variation. The prevalence of 
infection varies with socioeconomic status, living condition, and 
hygienic practices , antibody prevalence may be moderate (40-70%) in  
adults, in high socioeconomic group in developed countries in contrast 
to prevalence of 90% in children and adults in developing nations and 
in low socioeconomic group in developed countries. Human are only 
known host for cytomegalovirus (Jawetz et al., 2004). And infection 
rate are higher in non whites than in whites Human (knipe et al., 
2001).  
2.4.2. Molecular epidemiology 
Molecular tools have improved knowledge of the epidemiology 
of CMV infection by providing laboratory evidence for suspected 
sources of infection and routes of transmission. A number of 
approaches have been used (traditional hybridization, restriction 
fragment length polymorphism (RFLP), Sequence PCR, Nucleotide 
Sequence, Selected genes). All are based on the general premise for 
epidemiology linked isolates for Human CMV. Extensive nucleotide 
sequence homology, and further more that are not epidemiology –have 
sequence diversity that is readily detectable. The envelope 
glycoprotein genes from clinical isolates have been sequenced and 
compared. Chou and Dennison et al (1991) found that, clinical strains 
and laboratory strains Towne and AD169 could be grouped in to one 
of for gB genotypes (Knipe et al., 200l).             
2.5. Transmission and spread of HCMV 
CMV is not high contagious agent and transmission appears to 
be requiring direct contact with infectious material. Following initial 
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acquition of CMV, infectious virus is present in urine, saliva, tears, 
semen and cervical secretion from month to years. High rates of CMV 
infection occur in settings where close contact with body fluid is 
expected, Such as between sex partners, among children in day care 
centers, and between preschool-aged children. But transmission of 
CMV through the sexual contact is an important means of spread, and 
the prevalence of CMV infection is higher among populations with 
other markers of sexual activity; such as greater number of partner and 
sexually transmitted diseases and among sexually active adolescent 
(knipe et al ., 2001). CMV virus is unique among the human 
herpesviruses in the transmission from mother to fetus or newborn so 
that it plays an important role in maintaining CMV in population. 
Human CMV spread from mother to baby by three major routes; 
transplacental, intrapartum and human milk (knipe et al., 2001). The 
virus can also be transmitted by organ transplants and by blood 
transfusion (William et al., 2001).   
2.6. Cytomegalovirus and immunocompramised patient 
 Individuals at greatest risk for cytomegalovirus disease are 
those receiving organ transplants, those with malignant tumors who 
are receiving chemotherapy and those with AIDS. Both morbidity and 
mortality rate increased with primary and recurrent cytomegalovirus 
infection in immunocompramised individual. Iintertstial pneumonitis 
caused by cytomegalovirus occurs in 10 to 20 % of bone marrow 
transplant recipients. Virus associated leucopenia is common in solid 
organ transplant recipient, graft atherosclerosis after heart 
transplantation and cytomegalovirus related rejection of renal 
allograft. Cytomegalovirus often causes disseminated disease in 
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untreated AIDS patient; gastroenteritis and chorioretintis are common 
problem (Jawetz et al., 2004). 
2.6.1. Human cytomegalovirus and renal transplant patients 
Symptomatic CMV infection occurs in 20 to 60% of all 
transplant recipients and is a significant cause of increased morbidity 
and mortality in this population (Brennan and Singer, 1999; Sai and 
Patel, 2000). The incidence may be somewhat lower in kidney 
transplant recipients who do not receive antilymphocyte therapy, high-
dose mycophenolate, or the potent combination of mycophenolate and 
tacrolimus without adequate antiviral prophylaxis.  
Historically, concern has focused mainly on avoiding CMV 
infection in the CMV D+/R- group because this group has been at 
greatest risk for severe “primary” infection during the first 3 months 
after transplantation. However, the indirect effects of CMV infection 
on graft and patient survival have been increasingly recognized in 
recent years. The analyses of data from the United States Renal Data 
System and United Network of Organ Sharing revealed that by 3 
years, it is the D+/R+ group and not the D+/R- group that have the 
worst graft and patient survival (Schnitzler et al., 1997). The reason 
for this is not entirely clear but may reflect the prevalence of multiple 
CMV virotypes and that the D+/R+ patients may have a double CMV 
exposure with reactivation of differing latent donor and recipient 
CMV. CMV can predispose to rejection as well. Subclinical CMV 
may also mimic and or predispose to late acute rejection. Late 
subclinical infections are common and associated with relatively rapid 
graft loss (Kern et al., 1996). 
CMV has been associated with both atherosclerosis and chronic 
rejection, and the two most common causes of late graft loss are 
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cardiovascular death and chronic rejection. Chronic rejection is also 
known as chronic allograft nephropathy and is characterized by 
myointimal thickening, which is a form of atherosclerosis. Latent 
CMV infection has been associated with a markedly increased rate of 
restenosis (1200% higher) after coronary angioplasty in non-transplant 
seropositive individuals compared with seronegative individuals 
(Zhou et al., 1996). Furthermore, the histologic lesion of coronary 
restenosis is diffuse atherosclerosis characterized by myointimal 
hyperplasia resembling chronic rejection. CMV is believed to affect 
this process in part by blocking the antiproliferative effects of p53 
(Speir et al., 1994). However, more recent evidence suggests that the 
myointimal increase is not from proliferation but rather from 
migration of smooth muscle cells (SMC) mediated by virally encoded 
chemokine receptors that require tryosine kinase for expressions 
(Streblow et al., 1999). SMC migration could be blocked by tryosine 
kinase inhibitors and suggests another potential future therapeutic 
strategy. Finally, human CMV infection may also cause 
atherosclerosis and chronic rejection by increasing oxidized low 
density lipoprotein uptake by vascular SMC (Zhou et al., 1996). This 
process is mediated by the IE gene IE72 and does not require viral 
replication, which may explain why angioplasty patients who were 
infected latently with CMV had higher rates of restenosis after 
angioplasty. CMV has been associated with several other vascular 
injuries that may explain why the D+/R+ group has the worst overall 
survival. One such vascular injury associated with CMV is transplant 
glomerulopathy. However, the frequency and clinical significance of 
this lesion are uncertain (Birk and Chavers, 1997). The lesion of the 
hemolytic uremic syndrome/thrombotic microangiopathy is one of the 
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more common vascular pathologies associated with CMV and may be 
confused with or present with cyclosporine or tacrolimus toxicity 
(Miller et al., 1997; Hochstetler et al., 1994). CMV-associated 
hemolytic uremic syndrome/thrombotic microangiopathy may respond 
to Ig infusion (Hochstetler et al., 1994). CMV has been implicated as 
an important contributor to restenosis of coronary arteries after 
angioplasty in nontransplant patients (Zhou et al., 1996). CMV has 
also been associated with transplant renal artery stenosis. In a study of 
more than 900 renal transplant recipients, 75 were diagnosed with 
renal artery stenosis via angiography (Pouria et al., 1998).  
2.6.2. Human cytomegalovirus and HIV patients 
Cytomegalovirus (CMV) causes the most common viral 
opportunistic infection in the persons with acquired 
immunodeficiency syndrome (AIDS).The Clinical disease due to 
CMV has been recognized in up to 40 % of patients with advanced 
HIV diseases (Jacobson et al., 1988). The clinical manifestations of 
CMV diseases do not generally present until the CD4 count drops 
below 100 CD4 cells / mm3 (Palestine et al., 1991). Risk of CMV 
disease is linked closely with immune impairment as reflected by low 
CD4 T-cell conunts. The clinical manifestations among the patients 
with CMV diseases was retinitis , esophagitis , colitis ,and less 
common clinical presentations of CMV diseases in AIDS patients 
include encephalitis, peripheral neuropathy, polyradiculoneuritis, 
pneumonitis, gastritis and hepatitis. 
       Cytomegalovirus has been suspected being a cofactor in the 
development of AIDS because the clinical studies linked CMV and 
progression of HIV-1 infection. And the laboratory studies provide a 
biologic frame work for CMV enhancement of HIV-1 infection. 
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proposed mechanisms through which CMV could enhance HIV-1 
replication or reactivation from latently infected cells include 
transactivation of promoter in the HIV-1 long terminal repeat, 
induction of FC receptor expression and immune activation with 
production of proinflammatory cytokine (Kinpe et al ., 2001).    
 2.7. Congenital Human cytomegalovirus  
Fetal and newborn infection with cytomegalovirus my be sever. 
About 1% of live birth annually in the United States has congenital 
cytomegalovirus infection and about 5-10% of those will suffer 
cytomegalic inclusion diseases. A high percentage of babies with 
these diseases will exhibit developmental defects and mental 
retardation. The virus can be transmitted with both primary and 
reactivated maternal infection. About one –third of pregnant women 
with primary infection transmit the virus congenital infection may 
result in death of fetus in utero. Cytomegalic inclusion disease of 
newborns is characterized by involvement of central nervous system 
and the reticuloendothelial system. Clinical features include 
intrauterine growth retardation, jaundice, heptosplenomegaly, 
thrombocytopenia, microcephaly, and retinitis. Mortality rates can 
approach 30%. The majority of survivors will develop significant 
central nervous system defect within 2 years; sever hearing loos, 
ocular abnormalities, and mental retardation is common. About 10 % 
of subclinical congenital cytomegalovirus infection will develop 
deafness (Jawetz et al., 2004). Ten percent of these infants are born 
symptomatic, manifesting various neurologic, hematologic, and 
developmental abnormalities (Demmler, 1991).  
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2.8. Stability of Human cytomegalovirus 
CMV is a labile virus and readily inactivated by lipid solvents, 
pH below 5, heat (37°C for 1 h or 56°C for 30 min), and ultraviolet 
light for 5 min. It can survive on environmental surfaces for several 
hours. CMV can be stored at 4°C for a few days without loss of 
infectivity. Storage at –70°C without loss of infectivity is possible for 
several months. CMV can be stored at –190°C (liquid nitrogen) 
indefinitely (Daniel, 2001).                     
2.9. Persistence of Human cytomegalovirus 
Human CMV persists within its host indefinitely; there is 
growing evidence that cells in bone marrow and peripheral blood are a 
key reservoir for CMV through latent infection. A small percentage of 
peripheral blood monocytes from subjects with the past infection 
harbor CMV DNA. But viral gene expression is limited to early genes. 
However; tissue macrophage early and late CMV antigens. Kondo et 
al (1994). showed that granulocyte macrophage progenitors from 
human fetal liver and bone marrow could be latently infected in vitro; 
the cells have a CD14-, CD15-, CD33-, phenotypic and expressed {E} 
early transcripts. Soberberg – naucler et al (1997) reported 
reactivation of CMV in vitro by allogenic stimulation from peripheral 
blood mononuclear cells. The experimental evidence supports a model 
of CMV persistence which myelomonocytes stem cells resident in 
bone marrow maintain latent infection, and latently infected CD14+ 
monocytes circulate in peripheral blood, differentiation latently 
infected monocytes into tissue macrophages result of  allogenic 
stimulation (transciplantation) or triggering of proinflammatory 
cytokines as intercurrent infection leads to productive infection (knipe 
et al ., 2001). 
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2.10. Reactivation of HCMV infection 
Reactivation is believed to be more important than primary 
infection as a virus causing disease in immunocompromized host and 
is though to occur as a result of at least three collaborating events: 
a. Cytokine stimulation of latently infected cells causing 
differentiation into a permissive cell type that supports viral 
replication (Hahn et al., 1998). 
b. Viral amplification caused by reduced immune surveillance that 
leads to wide spread systemic infection with readily detectable 
viraemia (Farrel et al., 1999) and virus in many tissues. 
c. Disease state develops as a result of poorly understood 
collaboration of immune-organ and virus species determinants. 
The three stages of reactivation help illuminate on important 
interplay of the immune response in reactivation and pathogenesis 
(Farrel et al., 1999). Immunocompromized individuals who support 
persistent infection or who frequently reactivate and shed viruses may 
be predisposed to more rapid amplification and clinical disease 
because the first event is unnecessary. Most clinical manifestation of 
reactivation results from second events, after virus replication reaches 
high systemic levels prior to and the absence of disease is the basis of 
preemptive antiviral or adoptive CMV specific CTL therapies (Riddel 
and Greenberg, 1997). As well as being the basis for the dramatic 
reduction in incidence of CMV retinitis and gastroenteritis resulting 
from immuno reconstitution that follows highly active retoviral 
therapy in AIDS patients (Donniger et al., 1999). The earliest event in 
reactivation is fascinating area virus biology. Cytokine mediated 
differentiation of peripheral blood monocytes into macrophages under 
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strongly proinflammatory conditions is undoubtedly key to this 
process (Meier and Stinski, 1996).                  
2.11. Diagnosis of Human cytomegalovirus 
There are several methods for diagnosing CMV. Until fairly 
recently, the available techniques for diagnosing CMV were limited to 
histologic identification of CMV inclusion bodies, viral culture, and 
serology. These techniques are labor intensive and not completely 
sensitive, and the time from primary infection or reactivation to 
detection of CMV is protracted, allowing for undetected and untreated 
disease progression. In addition, transplant recipients may fail to 
produce an antibody response despite other evidence for viremia, 
making the newer techniques preferable to serology for detection and 
monitoring. Newer techniques include shell vial culture, pp65 
antigenemia assay, PCR, and the hybrid-capture RNA-DNA 
hybridization assay, which has recently received FDA clearance for 
the qualitative detection of CMV-DNA (Storch, 2000).  
2.11.1. Histopathology 
Characteristic large cells with intranuclear and, on occasion 
cytoplasmic inclusion can be seen in routine section of biopsy or 
autopsy material. Wright –Giemsa stained touch imprints of lung or 
other biopsy speciment may demonsrate such cells. Although the 
presence of characteristic cytological changes suggests CMV 
infection. Virological serological conformation is suggested since 
CMV can infect tissues without producing morphological changes. 
Failure to find typical cytomegalic cells does not exclude the 
possibility of CMV infection (Hodinka et al., 1991). The large 
inclusions are intranuclear and have a characteristic owl-eye 
appearance in haematoxylin and eosin stained tissue specimens. The 
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positive results correlate well with active HCMV infection of the 
organ, e. g. hepatitis, but the sensitivity of the histopathological 
finding is relatively low (Colina et al., 1995; Mattes et al., 2000). 
Immunostaining with specific polyclonal or monoclonal antibodies 
against HCMV antigens has increased the sensitivity of the method 
compared to conventional staining (Barkholt et al., 1994; Paya et al., 
1990). Although the histological methods may have an important role 
in detecting HCMV organ involvement, they are not suitable for the 
early diagnosis of HCMV infection. In addition, these assays are very 
laborious, and biopsy specimens are only taken when an end-organ 
disease is suspected. 
2.11.2. Serology 
Serological tests for antibody to CMV are useful to determining 
whether a patient had CMV infection in the past, a determination of 
great clinical importance for organ and blood donors, and in 
pretransplant evaluation of prospective transplant recipients. In 
addition, serologic test for seroconvertion and for IgM antibody to 
CMV are commonly used to establish whether or not infection in the 
normal host occurred recently. A variety of different laboratory 
methods have been used successfully to measure antibody to CMV. 
Traditionally, serologic evidence of recent primary CMV infection 
depended on the demonstration of conversion from IgG antibody 
negative to positive are demonstration of IgM antibody (Kinpe et al., 
2001). 
2.11.2.1. Enzyme linked immunsorbent assay (ELISA) 
Enzyme linked immunsorbent assay (ELISA) is the most 
commonly available serologic test for measuring antibody to CMV. 
The result can be used to determine whether it is due to acute 
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infection, previous infection, or passively acquired maternal 
antibodies in an infant. ELISA also is proved to be a useful technique 
when recombinant antigens are used to differentiate between primary 
and secondary or past CMV infection in pregnancy, it was found that 
IgM response to recombinant proteins and PP150 in primary infected 
women varies. Predominant IgG response to P52 was observed in 
early sera less than 4 weeks after seroconversion, whereas IgG 
response to recombinant proteins PP150 was delayed and appeared 2-
7 weeks later. On the other hand women with secondary and those 
with post primary infection had IgG antibodies to PP150. ELISA for 
CMV specific IgM may give false positive result unless steps are 
taken to remove rheumatoid factor (Daiminger et al., 1998). 
2.11.2.2. Immunofluorescence Test (IFT)  
This test is slightly faster but has the disadvantage that the assay 
should be performed on monolayer of infected cells; specific nuclear 
fluorescence which indicates a positive result is sometimes difficult to 
distinguish from nonspecific cytoplasmic fluorescence. For 
performance the test, fibroblasts are growing in cell culture slides and 
infected with CMV (generally the strain AD-169). When CPE is 3 to 
4+ (3days after incubation) cells are fixed in cold acetone and stored 
or used directly. Human sera are serially diluted and allowed to react 
with infected fibroblasts. Slides are incubated in moist chamber, 
washed, and stained with optimal dilution of fluorescein-conjugated 
anti human IgG. After incubation slides are washed and mounted for 
microscopic reading (Hodinka et al., 1991).         
2.11.2.3. Immunoblot 
The immunoblot for detection CMV specific IgM in human 
Sera is a new diagnostic technique. Four viral proteins (vp150, vp82, 
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vp65 and vp28) and 4 recombinant proteins (rp150, jp130, jpp52, and 
andrp38) were purified from Escherichia coli. These antigens were 
individually loaded into nitrocellulose stripe with specific conjugate in 
detection of CMV specific IgM. The immunoblot tests combine high 
sensitivity and specificity (Lozzarotto et al., 1998).      
2.11.3. Conventional tube culture 
Human fibroblast cells best support the growth of CMV and 
therefore are used for diagnostic purposes. Acceptable fibroblast 
cultures include those prepared from human embryonic tissues or 
foreskins and serially passaged diploid Human fetal lung strains such 
as WI-38, MRC-5, OR IMR-90.The time of appearance and the extent 
of CPE depend on the amount of the virus present in the specimens 
(Hodinka et al., 1991). 
Infectious virus can be isolated from various clinical materials, such 
as bodily secretions, tissue or peripheral blood, in cell cultures which 
are permissive for HCMV replication. Human fibroblast cell cultures, 
obtained from the foreskin or from the embryonic lung tissues, have 
been used for conventional and shell vial methods for the isolation of 
HCMV 21 (Mendez et al., 1999). In conventional viral isolation 
methods, commonly used in earlier times, determination of viral 
replication is based on typical cytopathic effects (CPE) produced by 
HCMV. The time required for the development of CPE usually varies 
from 2 to 4 weeks, even up to six weeks. Several less time-consuming 
methods have been developed for the isolation of infectious virus 
(Mendez et al., 1999; Sia and Patel, 2000).  The isolation of HCMV 
from the blood or target organ specimen by cell culture methods has a 
high correlation with disease. However, the relatively low sensitivity 
of detection of the virus in blood samples compared to nucleic acid-
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based and antigenemia methods, limits the use of these assays in the 
diagnosis and monitoring of HCMV infection in transplant patients 
(Badley et al., 1996; Evans et al., 1999; Wirgart et al., 1996). 
Isolation of the virus from peripheral sites (such as urine or saliva) 
may be used to demonstrate asymptomatic shedding of HCMV in the 
throat or urinary tract. On the other hand, viral culture may be helpful 
in detecting HCMV from bronchoalveolar lavage (BAL) or biopsy 
specimens in the organ specific infection. Nevertheless, detection of 
the virus from the blood of immunocompromised patient is a sign of 
viremia and is always considered as a serious finding. Furthermore, 
positive virus isolation from any site of a seronegative recipient is a 
clear indication of primary infection, which may rapidly progress to a 
severe disease. However, viral culture is a qualitative method with a 
limited role in the diagnosis of HCMV infection. In cultures 
inoculated with urine from a congenitally infected newborn CPE may 
develop by 24 h and progress rapidly to involve most of the 
monolayer if the virus titer of the urine is extremely highly. More 
commonly, foci of CPE, consisting of enlarged, rounded refractile 
cells appear during the first week and progression of CPE to 
surrounding cells proceeds slowly (Hodinka et al., 1991).                                   
2.11.4. Shell vial assay 
The shell vial culture is rapid modification of conventional cell 
culture. In this technique the virus is detected more quickly because 
infected cell monolayer is stained for viral antigens found soon after 
infection before the development of CPE. For this it is best used for 
viruses require relatively long incubation befor producing CPE such 
as CMV (Forbes et al., 1998). Shell vial cultures differ from 
conventional cell culture techniques. 5ml of EDTA – treated blood is 
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allowed to sediment by gravity and the leukocyte- rich plasma is 
removed and centrifuged. The pellet is washed twice with Eagles 
minimal essential media, and then is resuspended in 1ml of   Eagles 
minimal essential media with 10% fetal bovine serum. However 
conventional cell culture with human embryonic lung fibroblast cell 
(HEL299 American type culture Collection), is inoculated with 1ml of 
cell suspension conventional cell are maintained for 4 weeks. Three 
shell vials prepared weekly with MRC-5 cell are inoculated with 
0.3ml of cell suspension centrifuged at 700g for 40 minutes, at 20 to 
30°C. Cover slips from shell vial are fixed, stained with fluorescein –
isothiocyanate- labeled CMV monoclonal antibody and examined 
after 48 hours (Tony et al., 1993).  
2.11.5. Antigenemia assay 
The antigenemia assay, first described by Professor The and his 
associates (van den Berg et al., 1989) has been a major advance in the 
diagnosis of HCMV infection in transplant patients. In this test, 
monoclonal antibodies to pp65 (UL83) (Depto and Stenberg, 1989; 
Gerna et al., 1992; Grefte et al., 1992), the lower matrix protein, are 
used for the direct immunostaining of blood polymorphonuclear 
leukocytes (PMNL). However, it has been shown that the pp65 
antigen in PMNLs is not a direct indication of virus replication in 
vivo, since the virus and viral material detected in PMNLs are 
transferred from other infected cells, e.g. endothelial cells, mainly by 
microfusion events (Gerna et al., 2000). Nevertheless, the pp65 
antigenemia assay has been successfully used in the diagnosis of 
HCMV in transplant patients since the late 1980’s. 
     The pp65 antigenemia assay consists of numerous steps, including 
isolation of PMNL, fixation, immunostaining, and microscopic 
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evaluation and quantization (The et al., 1995; The et al., 1990; van 
den Berg et al., 1989). Dextran sedimentation or direct erythrocyte 
lyses can be used for isolation of leukocyte populations of blood. The 
isolated leukocytes are then cytocentrifuged onto glass slides and 
indirect immunoperoxidase or immunofluorescense staining is used 
for immunodetection of the HCMV antigen. After microscopic 
evaluation, quantitative results are expressed as the number of HCMV 
positive leukocytes per number of cells evaluated, usually per 50 000 
or 200 000 leukocytes. The whole process can be performed within 
one day. The antigenemia assay is more sensitive than cell culture 
methods in detecting HCMV in the blood (Landry and Ferguson, 
1993; van den Berg et al., 1991). It is also highly specific for HCMV 
but a positive result does not always predict the onset of symptomatic 
infection (Landry and Ferguson, 1993; Sia and Patel, 2000; Tanabe et 
al., 1997). Nevertheless, when using the test in a quantitative manner, 
the assay can be used to predict and diagnose HCMV infection: at 
least, a higher degree of antigenemia is correlated with symptomatic 
disease, as has been shown by many groups (Hadaya et al., 2003; 
Humar et al., 1999; Kim et al., 2003). One disadvantage of the 
antigenemia assay is that the blood samples should be processed 
within a certain time, preferably within six hours, for optimal results 
(Schafer et al., 1997). In addition, though there have been attempts to 
simplify the method (Gratacap-Cavallier et al., 2003; Ho et al., 1998), 
it is still quite time-consuming and laborious, at least with large 
specimen numbers. The automation of the test is also difficult because 
of the number of steps and the subjective evaluation of the infected 
leukocytes. Although there have been attempts to standardize the 
assay (Gerna et al., 1998; The et al., 1995; Verschuuren et al., 1999), 
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there are a number of various in-house and commercial modifications 
available. This makes comparison of the results between different 
centers difficult. The clinically significant threehold of the number of 
positive leukocytes seems to vary also among different types of 
transplant populations (Baldanti et al., 1998; Razonable et al., 2002b). 
In any case, the pp65 antigenemia test has shown its clinical utility in 
the diagnosis of HCMV infection, in guiding of pre-emptive therapy, 
and also in the monitoring of response to antiviral treatment (Kusne et 
al., 1999). 
2.11.6. Molecular techniques 
The widespread introduction of the application of nucleic acid 
amplification technologies has been the most important improvement 
in HCMV diagnostics in the past decade. The most frequently used 
methods are based on PCR detecting HCMV DNA or (RNA) in whole 
blood or in different blood compartments. Both qualitative and 
quantitative assays have been used. However, understanding of the 
correlation between viral loads and clinical symptoms has diminished 
the significance of qualitative methods. Different kind of quantitative 
PCR assays, both in-house and commercial ones, have been 
employed. The in-house assays, based on competitive PCR, are 
usually technically complicated. Commercial and real-time based 
applications, which are more convenient and faster, are more widely 
used at present. Also other nucleic acid-based techniques, such as 
nucleic acid sequence based amplification (NASBA) and signal 
amplification (Hybrid Capture System) have successfully been used in 
the detection of viral mRNA or DNA, respectively. 
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2.11.6.1. Polymerase chain reaction PCR 
Polymerase chain reaction (PCR) method is considered a 
valuable tool for diagnosis in Virology due to a high sensitivity that 
allows detection of very low a mounts of DNA in clinical samples 
(Pellegrin et al., 1999).  
  PCR is a rapid and simple technique with high sensitivity and 
specificity. In recent years, PCR has been used for rapid detection of 
viral nucleic acid, such as human cytomegalovirus, whereas, PCR 
Optimization is an important task to be done, especially befor it's 
diagnostic an application (Bavil et al., 2003). PCR uses two 
oligonucleotides (primers), Complementary to sense and antisense 
strands of a defined DNA fragment, a (heat –stable) DNA polymerase 
and several cycle of denaturation, primers annealing and extension is a 
technique for amplifying specific nucleic acid in vitro (Scharf et al., 
1986). In same study, it has been reported that the use of Polymarase 
chain reaction in detection of human CMV in peripheral blood 
samples showed sensistivity reaching up to 5 fg  microliter (Wong et 
al., 1997). 
2.11.6.2. Hybrid Capture CMV DNA Assay   
The hybrid capture system (Digene Corp) is a solution 
hybridization assay that involves amplified chemiluminescent 
detection. Specimens containing the target DNA hybridize with a 
specific CMV RNA probe complementary to approximately 40,000 bp 
or 17% of the CMV genome. The resultant RNA-DNA hybrids are 
captured onto the surface of a tube coated with antibodies specific for 
RNA-DNA hybrids. The immobilized hybrids are then reacted with 
alkaline phosphatase- conjugated antibodies specific for the hybrids 
and detected with a chemiluminescent substrate. Because each 38-kb 
 ٢٨
RNA-DNA hybrid binds approximately 1,000 antibody conjugate 
molecules, each of which is bound to about 3 alkaline phosphatase 
molecules, the resulting signal is amplified at least 3,000-fold. The 
amount of light emitted, which is measured as relative light units on a 
illuminometer, is proportional to the amount of target DNA in the 
specimen (Michael and Guy, 1998). 
2.11.6.3. Nucleic acid Sequence-based amplification (NASBA) 
The nucleic acid sequence based amplification technique has 
been used in early detection of CMV infection in kidney 
transplantation because the viral immediate early (IE) messenger RNA 
expression in blood leukocyte. However the technique provide to be 
most sensitive assay that detected the onset of both primary and 
secondary cytomegalovirus  infection that enabled the start of 
effective antiviral therapy in the patient at risk ( Block et al.,1999 ). 
The same technique was done , in which human cytomegalovirus  
pp67 was used in bone marrow transplant recipient, it was found that 
the NASBA detect CMV infection befor quantification of viremia by 
PCR, the sensitivity reached 100% while the specificity 68.9% (Gerna 
et al., 1999).   
2.11.6.4. Insitu DNA hybridization 
            Molecular dot blot hybridization techniques have been 
described for detection of the CMV genome in urine and peripheral 
blood leukocytes. Recently, in situ hybridization has been used for the 
direct detection of CMV in formalin fixed lung, Kaposi's sarcoma 
tissue and peripheral blood leukocytes. Biotinylated or horseradish 
peroxidase- labeled CMV specific DNA probe kits are commercially 
available. In situ hybridization has advantage of being rapid and easy 
to read by light microscope. However current methods lack the 
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sensitive needed for routine use in clinical laboratories (Hodinka, 
1991).          
2.12. The immune system and CMV 
Because most immunocompetent individuals do not suffer from 
CMV disease during either primary or recurrent infections, the 
immune system must be effective in controlling replication. However, 
this simplistic assumption masks a level of complexity between the 
virus and host that is still being unraveled. The B cell response to 
CMV is largely dominated by an anti-glycoprotein B cell response, 
and most of the neutralizing antibodies are also directed against this 
protein (Wagner et al., 1992; Ohlin et al., 1993). In contrast, the 
catatonic T cell (CD8) response is almost exclusively directed against 
the pp65 (UL83) protein and epitopes have been mapped for human 
major histocompatibility complex (HLA) types A (Wills et al., 1996; 
Mclaughlin et al., 1994). In the face of such an aggressive immune 
response, how does the virus survive. It is now clear that CMV 
encodes a range of gene products and uses several mechanisms to 
manipulate the host immune system (Ploegh, 1998). Thus, the 
presentation of immediate–early antigens is suppressed by 
phosphorylation by a virion phosphoprotein, which leads to a lack of 
processing within the proteasome (Gilbert et al., 1996). In addition, 
the HLA class I display pathway is interrupted at multiple time points 
after infection via interaction with the TAP system, the recycling 
system, and terminal maturation by genes US2, US3, US6, and US11 
(Ploegh, 1998). The consequences of reduced HLA class I display 
should result in an increased susceptibility to natural killer (NK) cell 
activity, because cells require presentation of the signal peptides 
derived from HLA class I A, B, or C to be protected against NK cell 
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lysis (Borrego et al., 1998). However, the CMV genome contains an 
HLA class I homologue (UL18), which is synthesized late in the viral 
replicative cycle, when HLA class I downregulation is maximal 
(Hassan Walker et al., 1998). In addition to encoding HLA class I 
dysregulatory genes, the genome encodes four potential G coupled 
protein receptors, one of which (US28) acts as a broad specificity ß 
chemokine receptor and can act as a coreceptor for the uptake of HIV 
(Pleskoff et al .,1997 ). The genome also contains two genes with 
homology to the CXC chemokine family (Chat et al., 1996). And one 
of these has been shown to stimulate neutrophil migration with the 
same potency as other cellular chemokines (Penfold et al., 1999).  
2.13. Vaccination against HCMV 
Although attempts to develop vaccine for prevention of 
maternal and congenital CMV have been made for over 25 years no 
vaccine is currently licensed or near licensure. However, 
investigational vaccines employing different formats have been 
evaluated in the clinical trials; these include attenuated live virus, 
recombinant protein in fowl pox vector and recombinant protein given 
with anew adjuvant. The Twne strain of CMV was passaged more 
than 125 times in vitro to achieve attenuation. Subsequent study 
showed that the Twne strain of CMV was attenuated in that it did not 
produce a febrile illness in challenge studies wheras allow passage 
Toledo strain did. Immunization with Twine strain CMV vaccine 
induces both antibody responses and lymphocyte proliferative 
response to CMV. An efficacy trial in renal transplant recipient 
patients showed that pretransplantation immunization of seronegative 
patients with Twne strain CMV vaccine protected than from sever 
disease although it did not prevent infection (Knipe et al., 2001).           
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2.14. Treatment 
         The three antiviral drugs that are currently licensed for the 
treatment of HCMV infection are ganciclovir (GCV), foscarnet and 
cidofovir. Ganciclovir is the drug of choice in the treatment of 
symptomatic infections. Ganciclovir is a specific nucleoside analog 
which first is phosphorylated before it gains antiviral activity (Littler 
et al., 1992; Sullivan et al., 1992). The initial phosphorylation is 
mediated by virus encoded phosphotransferase (product of UL97). 
The monophosphate form is further phosphorylated by the host’s 
cellular kinases into the active triphosphate form, which inhibits viral 
DNA polymerase by competing with deoxyguanosine triphosphate 
(Noble and Faulds, 1998). Foscarnet is an inorganic pyrophosphate 
analog and directly inhibits viral DNA polymerase (Crumpacker, 
1992). However, foscarnet is nephrotoxic, which limits its use in 
kidney transplantation. Intravenous cidofovir may also be used, but 
experience of this agent in solid organ recipients is still very limited. 
Cidofovir is a cytosine analog which does not require the virus 
encoded phosphotransferase activity. Instead host cellular enzymes 
carry out the phosphorylations needed for activation (Lalezari et al., 
1995; Snoeck et al., 1988). Valganciclovir, a pro-drug of ganciclovir, 
is a new promising compound which is administered orally and has an 
increased bioavailability compared to that of oral ganciclovir 
(Pescovitz et al., 2000). Nowadays valganciclovir is used in therapy of 
HCMV disease; however, more clinical trials are needed. The HCMV 
hyperimmunoglobulin may also be used in some patient groups in 
combination with antiviral drugs.  
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2.15. Prevention 
      Specific control measure is not available to prevent 
cytomegalovirus spread. Screening of transplant donors and recipient 
for cytomegalovirus may prevent some transmission of primary 
cytomegalovirus. The cytomegalovirus seronegative transplant 
recipient population represents a high risk group for CMV infection 
(Jawetz et al., 2004). In organ transplantation the common source of 
CMV infection is reactivation of transplant recipient latent virus, and 
there is no means to prevent this infection. Although selection of 
seronegative donors for seronegative recipients will prevent primary 
CMV infection in solid organ transplants recipient (Knipe et al., 
2002). The leukocyte free blood products are used for transplant 
patients. WBC is main source of CMV infection in peripheral blood 
products have been shown to reduce the Risk of CMV transmission. 
There is no effective vaccine against HCMV. Before the development 
of suitable antiviral drugs against HCMV, a reduction in the 
immunosuppressive regimen was used to prevent HCMV disease in 
transplant patients. However, this often led to an increased incidence 
of graft rejection (Sia and Patel, 2000; Knipe et al., 2002). CMV 
immunoglobulin were also used then  administration of human Ig 
prepared from plasma pools obtained from healthy persons with high 
titer of CMV antibodies has given discordant results in tests to 
decrease the incidence of the viral infection in the transplant recipients 
(Jawetz et al., 2004). Currently, good availability of antiviral agents 
allows maintenance of the level of immunosuppression required to 
prevent graft rejection. Two different strategies, prophylaxis and pre-
emptive therapy, are used for the prevention of symptomatic HCMV 
infection after transplantation. In prophylaxis, antiviral drugs are 
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administered before any evidence of the virus, and in pre-emptive 
therapy, antiviral drugs are administered when there is laboratory 
evidence of active but asymptomatic infection Also hyper 
immunoglobulin in combination with ganciclovir has been used in 
certain patient groups, e.g. lung transplant recipients (Weill et al., 
2003).In community use of good hand washing and careful hygiene 
have been recommended as mean to prevent CMV infection in precare 
workers and parents of young children (Knipe et al.,  2002).  
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 CHAPTER THREE  
MATERIALS AND METHODS 
3.1 Collection of samples: 
A total of 100 blood samples were collected from different 
patient groups in Khartoum State between January and April 2007. 
Data on respondent background, ideas, attitudes, and behavior 
on various issues in form of questionnaire were collected. The groups 
include: 
1.  Renal transplant recipients group: 52 Blood samples were 
collected from renal transplant recipients in the Sudanese 
Kidney Transplanted Association Center.  
2.  Haemodialysis patient group:  48 Blood samples were collected 
from Haemodialysis patients at Sudanese Kidney Transplanted 
Association Center, Khartoum North. 
Venous blood samples were collected using vacutainer and 
needles. The blood was drown into the tube without any anticoagulant 
and the blood was allowed to clot at room temperature for no more 
than 1 hour. The serum was removed and placed in sterile capped 
microfuge tubes and the tubes were centrifuged at 1000 rpm for 5 min 
at 4ºC. The serum was then removed without disturbing the pellet and 
the tubes were stored at -20ºC till used.  
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3.2 ELISA for detection of HCMV IgG antibodies in serum 
samples: 
     The ELISA Kits were purchased from Equipar Diagnostici 
Co.LTD, ITALY and supplied as follows: 
1. Microtiter plate 12×8 wells (96 tests) strips sealed in a flexible bag 
with desiccant. 
2. Negative control: 1 vial of 1×2.0 ml A.1=0.3 ready to use contains 
serum proteins and thimerosal (0.1%) as preservative. 
3. Low positive control Standard: (cut –off) 1 vial of 1×2.0 ml A.1 
ready to use value is stated on the vial. Contains serum proteins and 
thimerosal (0.1%) as preservative. 
4.  High positive Standard: 1 vial of 1×2.0 ml A.1 ready to use value 
is stated on the vial. Contains serum proteins and thimerosal (0.1%) as 
preservative. 
4. Sample diluent: 2 bottles of 50 ml each. Ready to use. Contains 
PBS/Tween. Protein stabilizer and thiomerosal (0.1%) as preservative. 
6. Washing solution: 1 bottle of 50 ml × 20 concentrated, contain 
PBS/Tween which must be diluted (dilute to 1 liter with distilled 
water before use). 
7. Enzyme Conjugate: 1 vial of 1×12 ml ready to use Horseradish 
peroxidas Conjugated goat Anti-human IgG (Fcγ chain specific). 
Contains serum proteins and thimerosal (0.05%) as preservative. 
8. TMB- substrate: 1 vial of 1×12 ml contains TMB (tetramethyle 
benzedine). 
9. Stop Solution: 1 vial of 1×12 ml, it contain (0.3M H2SO4). 
10. Instruction manual: 1 Copy. 
11. Graph paper to prepare standard curve. 
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3.2.1 Other materials not included in the kit:   
1. Multichannel pipette and micropipettes capable of delivering 10 
and 100 µl. 
2. Test tubes for Sample dilution. 
3. Disposable pipette tips. 
4. Distilled or deionized water. 
5. An automatic microplate washer. 
6. Microplate mixer. 
7. Incubator with high relative humidity, at 37 ºC. 
8. Timer with 60 minute range.  
9. Absorbent paper. 
10. Microplate reader equipped with a 450 nm filter. 
3.2.2 Storage and stability of ELISA kits. 
         All kits components were stored at 2-8 ºC and used before 
expiry date on the label. The bag containing the microtiter plate 
should be brought to room temperature before opening to avoid 
condensation in wells. Unused strips have to be placed in bag 
containing with dessicant and firmly sealed before re-store at 2-8 ºC. 
The diluted washing solution is stored between 2-8 ºC. All other liquid 
reagents were   stored at 2-8 ºC. And handled carefully to avoid any 
environment contamination. The chromogene was storaged protected 
from the light.  
3.2.3 Test procedure:  
3.2.4   Preparation of reagents: 
         Reagents, test samples, controls, conjugate, diluted wash 
solution, substrate, aluminum bag containing the microplate and vial 
containing TMB, and were allowed to reach room temperature (20 – 
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25 º C) before running the assay. All liquid reagents were mixed 
before used. 
The concentrated washing solution 50 ml is diluted with 1 liter 
distilled water. All dilutions were made according to the manufacture 
instruction. 
3.2.5 Assay procedure:  
         Samples were diluted 1:100 with serum diluent (10µl serum in 
1ml serum diluent). 
Three wells were reserved for one negative control and two 
positive controls (low positive standard & high positive standard).100 
µl of positive controls was transferred into each of the two wells. 
100µl of the negative control was transferred in to the wells. 100 µl of 
each sample (serum) was distributed to the designated wells. The plate 
was covered with the plate sealer, and incubated for 15 minutes at 23-
25 ºC. After that, the adhesive plate cover was removed and each well 
was filled with approximately 300 µl diluted washing solution. This 
process was repeated five times , after the last washing the microtiter 
plate were blotted on absorbent paper to remove any excess liquid 
from the wells then 100µl of Enzyme Conjugate transferred in to each 
wells. The plate was covered again with fresh plate sealer, mixed 
gently and incubated for 15 minute at 23-25 ºC. Adhesive plate cover 
was removed and each well was filled with approximately 300 µl 
diluted washing solution. This process was repeated five times. 100µl 
of TMB Substrate was transferred in to each well of microtiterplate. 
The plate was covered again with fresh plate sealer, and incubated for 
5 minutes at 23-25 ºC. Then the reaction was stopped by adding 100µl 
of stopping solution to each well and mixing completely. The 
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microwell reader (spectrophotometer) was adjacent at 450 nm and 
absorbance of each well was read within 5 minutes. 
3.2.6 Interpretation of test results:  
a- Negative means: Absorbance of individual negative control 
values must be less than 1.0. 
b- Equivocal means: Absorbance of individual equivocal values 
must be less than 1.0-1.10.  
 c- Positive must be greater than 1.1.  
2.2. ELISA for detection of HCMV IgM antibodies in serum 
samples: 
      The ELISA Kits were purchased from Equipar Diagnostici 
Co.LTD, ITALY. And supplied as follows: 
1. Antigen coated Microtiter plate 12×8 wells (96 tests) strips sealed 
in a flexible bag with desiccant. 
2. Negative control:  1 vial of 1×2.0 ml A.1=0.3 ready to use contains 
serum proteins and thimerosal (0.1%) as preservative. 
3. Low positive control Standard: (cut –off) 1 vial of 1×2.0 ml A.1 
ready to use value is stated on the vial. Contains serum proteins and 
thimerosal (0.1%) as preservative. 
4.  High positive Standard:  1 vial of 1×2.0 ml A.1 ready to use value 
is stated on the vial. Contains serum proteins and thimerosal (0.1%) as 
preservative. 
4. Sample diluent: 2 bottles 2×50 ml bottles.  Ready to use. Contains 
PBS/Tween. Protein stabilizer and rheumatoid factor absorbent 
solution. 
6. Washing solution: 1 bottle of 50 ml ×20 concentrated, contain 
PBS/Tween which must be diluted (dilute to 1 liter with distilled 
water before use). 
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7. Enzyme Conjugate: 1 vial of 1×12 ml ready to use Horseradish 
peroxidase Conjugated goat Anti-human IgM (U chain specific). 
Contains serum proteins and thimerosal (0.05%) as preservative. 
8. TMB- substrate: 1 vial of 1×12 ml contains TMB (tetramethyle 
benzedine).                                                                                         
9. Stop Solution: 1 vial of 1×12 ml, it contain (0.3M H2SO4). 
10. Instruction manual: 1 Copy. 
11. Graph paper to prepare standard curve. 
3.3.1 Other materials not included in kit:  
1. Multichannel pipette and micropipettes capable of delivering 10 
and 100 µl. 
2. Test tubes for sample dilution. 
3. Disposable pipette tips. 
4. Distilled or deionized water. 
5. An automatic microplate washer. 
6. Microplate mixer. 
7. Incubator with high relative humidity, at 37 ºC. 
8. Timer with 60 minute range.  
9. Absorbent paper. 
10. Microplate reader equipped with a 450 nm filter. 
3.3.2 Storage and stability of ELISA kits. 
         All kits components were stored at 2-8 ºC and used before 
expiry date on the label. The bag containing the microtiter plate 
should be brought to room temperature before opening to avoid 
condensation in wells. Unused strips have to be placed in bag 
containing the dessicant and firmly sealed before re-store at 2-8 ºC. 
The diluted washing solution is stored between 2-8 ºC. All other liquid 
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reagents were stored at 2-3 ºC and handled carefully to avoid any 
environmental contamination. 
3.3.3 Test procedure:  
3.3.4 Preparation of reagents: 
         Reagents, test samples, controls, conjugate, diluted wash 
solution, substrate, aluminum bag containing the microplate and vial 
containing TMB, and were allowed to reach room temperature (20 – 
25 º C). Before running the assay all liquid reagents were mixed 
before used. The concentrated washing solution 50 ml is diluted with 
1 liter distilled water. All dilutions were made according to the 
manufacture instruction.                                                                                    
3.3.5 Assay procedure:  
Samples were diluted 1:100 with serum diluent (10µl serum in 1ml 
serum diluent). 
Three wells were reserved for one negative control and two 
positive controls (low positive standard& high positive standard).100 
µl of positive controls was transferred into each of the two wells. 
100µl of the negative control was transferred into the wells. 100 µl of 
each sample (serum) was distributed to the designated wells. The plate 
was covered with the plate sealer, and incubated for 15 minutes at 
25ºC. After that, the adhesive plate cover was removed and each well 
was filled with approximately 300µl diluted washing solution. This 
process was repeated five times , after the last washing the microtiter 
plate were blotted on absorbent paper to remove any excess liquid 
from the wells then 100µl of Enzyme Conjugate transferred into each 
wells. The plate was covered again with fresh plate sealer, mixed 
gently and incubated for 15 minute at 25 ºC. Adhesive plate cover was 
removed and each well was filled with approximately 300µl diluted 
 ٤١
washing solution. This process was repeated five times. 100µl of 
TMB Substrate was transferred into each well of microtiterplate. The 
plate was covered again with fresh plate sealer, and incubated for 5 
minutes at 25 ºC. Then the reaction was stopped by adding 100µl of 
stopping solution to each well and mixined completely. The microwell 
reader (spectrophotometer) was adjusted at 450 nm and absorbance of 
each well was read within 5 minutes.                                                                              
3.3.6 3.2.6 Interpretation of test results:  
a- Negative means: Absorbance of individual negative control 
values must be less than 0.90 
b- Equivocal means: Absorbance of individual equivocal values 
must be between 0.90-1.10. 
 c- Positive must be greater than 1.1.  
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3.4 Indirect Immunofluorescence technique for detection of 
anti - cytomegalovirus IgG in serum samples:  
       Indirect Immunofluorescence kit for detection and titration of 
anti- cytomegalovirus IgG antibodies in human serum were purchased 
from BIOCIENTIFICA S.A., Buenos Aires, Argentina and supplied 
as follows:                                                                                       
3.4.1 Materials Provided: 
1.  Slides with reactant areas containing infected cells and non- 
infected with cytomegalovirus. Each area includes a mixture of both   
infected and non infected diploid human fibroblasts attached to it. 
Mixtures contain about 5% or over nuclear inclusion per field.                         
2. 1 Vial × 0.2 ml. Contain IgG anti CMV positive control human 
serum with 0.01 thimerosal ready to use.                                                    
3. 1 Vial × 0.2 ml. Contain IgG anti CMV negative control human 
serum with 0.01 thimerosal ready to use.                                                    
4. 1 Vial × 0.2 ml. Contain fluorescein isothiocyanate –labeled human 
antigammaglobulin created in goat immunized with specific human 
IgG including stabilizing protein and sodium azide 0.1%.                     
5. Evans blue. 1 Vial × 5.0 ml.of Evans blue (counterstain) with 
sodium azide 0.1% ready to use.                                                                  
6. Mounting medium. 1 Vial × 5.0 ml of buffered glycerin; Ph = 8 ± 
o.5.                                                                                               
7. Phosphate buffer saline (PBS). 4 Foil bags.                                                              
8.  Cover slips. 
9. Instruction manual: 1 Copy 
3.4.2 Materials required but not provided:  
1. Speciment collection containers. 
2. Pipette and disposable tips. 
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3. Distilled water. 
4. Timer. 
5. Fluorescence microscope   
3.4.3 Storage and stability: 
The kit was stored in refrigerator (2– 8 ºC). The expiry date was 
observed. 
3.4.4 Preparation of of reagents:  
Reagents, test samples, bags containing slides with reactant 
areas, and cover slips, were allowed to reach room temperature (20 – 
25 ºC) before running the test. The concentrated fluorescein 
isothiocyanate –labeled human antigammaglobulin (Conjugate) is 
diluted 1/200 with PBS, and then added 10 µl of Evan blue per ml. All 
dilutions were made according to the manufacture instructions. The 
PBS was diluted by adding the content of 1 foil bag of PBS into a 1 
liter with distilled water.  
3.4.5 Test procedure: 
          Samples were diluted 1/40 by adding 0.01ml of specimen to 
o.40ml PBS and mixed well prior to testing. Slides with reactant areas 
were removed from sealed and placed on clean and leveled surface 
and used immediately and the test is performed in 120 minutes. Then 
one full drop of negative  control were transferred into reactant areas 
number one , one full drop of positive  control were transferred into 
reactant areas number two. One full drop of each diluted samples 
(serum) was distributed into designated reactant area and then 
incubated in humid chamber for 30 minutes at room temperature (20 – 
25 ºC). After that the slide was removed from the humid chamber and 
gently rinsed in PBS. And then the slides were washed 3 times with 
PBS for 5 minutes each. One drop (20 – 30 µl) of prepared conjugate 
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was added over each area in the slide and spreaded all over the area. 
The slides were incubated in a humid chamber for 30 minutes at room 
temperature (20 – 25 ºC) away from excessive light. Then the slide 
was removed from the humid chamber and gently rinsed with PBS. 
The slides were then washed 3 times with PBS for 5 minutes each, and 
immediately afterwards the mounting medium was added along the 
slide and the cover slips were gently placed on the slide. The slide was 
immediately read with the aid of flourescence microscope using the 10 
objective lens.  
3.4.6 Interpretation of test results: 
3.4.6.1 Fluorescence intensity gradients: 
       Fluorescence intensity gradients may be semiguntified according 
to the following guidelines. 
1.  4 (+): maximal fluorescence: bright apple green. 
2. 3 (+): less bright apple green fluorescence. 
3.  2 (+): distinct but faint apple green fluorescence. 
4.  1 (+): very faint apple green fluorescence.   
 (a) Negative result test: if the infected cells present a fluorescence 
below 1+ and have reddish –orange staining, or if the observed 
fluorescence doesn't corresponding to specified CMV nuclear 
inclusion specific pattern. 
(b) Positive result test: Sample positive for anti CMV IgG antibodies 
if a fluorescence pattern containing clearly distinct nuclear inclusion 
with intensity of 1+ or greater is found in 5 or more cell per field, the 
remaining cells having a reddish –orange staining.                          
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3.5 Polymerase chain reaction (PCR):  
3.5.1 DNA extraction:  
Viral DNA was extracted from serum samples by the GF-1 
Blood DNA extraction kit (GF-. Catalog No GF.BD-100-100 preps) 
(Vivantis  pte.ltd), which uses a specially treated glass filter 
membrane fixed in column to efficiently bind DNA in the presence of 
high salt. Mini-column spin technology DNA extraction was 
performed from serum. 180µl of buffer NL (Nuclei cell lysis 
solution), and 20µl of proteinase K (20mg/ml), (Appendix 1) were 
added to 2 ml Eppendorf tube containing 300µl of serum, and the 
mixture was mixed thoroughly by inverting tube, and was incubated at 
58 ºC for 20min in a shaking water bath. 20µl of RNase (DNase free), 
were added and the tube was mixed and incubated at 37ºC for 5 min, 
and 2 volumes of BB buffer were added and mixed thoroughly by 
inverting the tube several times until a homogeneous solution was 
obtained and incubate at 58 ºC for 10 min. The mixture was cooled 
down for 1 min. and 200µl of absolute ethanol was added 
immediately. The sample was transfered into a column assembled in 
clean 2ml collection tube. The column was centrifuged at 10000 xg 
for 1min. The flow was discarded through. The column was washed 
by addition of 750µl of washing buffer and centrifuged at 10000 xg 
for 1min and the flow was discarding through. The column was 
centrifuged at10000 xg for 1min to remove residual ethanol. The 
column was placed into a clean 1.5 ml Eppendorf tube, and 50µl of 
elution buffer (10Mm Tris-HCL, PH 8.5) was added directly into the 
column membrane and after 2 min, the column was centrifuged at 
10000 xg for 1min to elute DNA. Then the DNA was stored at -20 ºC 
until used.  
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3.5.2 Positive control  
10µl of positive control (provided with the kit) was used as 
positive control. 
3.5.3 Negative control  
10µl of DNA-Buffer (provided with the kit) was used as 
Negative control. 
3.5.4 PCR amplification: 
PCR was carried out using a ready-made PCR kit (SACACE, 
ITALY). PCR was performed in a final volume 40 µl according to 
manufacture instructions, including 10µl of PCR Mix2, 20µl of 
mineral oil, 10µl of template DNA were added to the PCR –Mix 1 
tube. And the amplification reaction was performed in a TP3 
Theromcycler (BIOMETRA, Coettingen, Germany). The programe 
used was 95 ºC 5min ; 95 ºC 1min , 67 ºC 1min , 72 ºC 1min; repeated 
for 42 cycles. 
3.5.5 Analysis of PCR Products: 
       The PCR products were analyzed by electrophoresis in 2% 
agarose gel (Appendix 2.1) stained with ethidium bromide 
(0.7µl/25ml agarose) (Appendix 2.5). 1µl of 100bp DNA ladder 
(Vivantes) was loaded in the first slot of the gel. The 10µl of PCR 
Products was mixed with 2 µl of loading Dye (Appendix 2.3) and 
loaded in the rest wells. Electrophoresis was performed in SCIE-PLS. 
gel electrophoresis (model no HU6), using 120 volt and 30 mA for 
45min after the gel was covered with TBE buffer (Appendix 2.2) 
using standard Power E802 (Consort). The bands were visualized 
using the BIO-RAD gel documentation system (BIORAD). 
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CHAPTER FOUR 
RESULTS 
       The over all result of testing 93 sera collected from renal 
transplant recipients and Haemodialysis patients by the four 
techniques is shown in appendix 3. 
4.1. ELISA results for CMV IgG 
51 out of 52 blood samples collected from renal transplant 
recipients (98%) gave positive results. On the other hand 39 out of 
41blood samples (95%) collected from Haemodialysis patients gave 
positive results (Table 1& appendix 4).                                                                         
4.2. ELISA results for CMV IgM  
3 out of 52 blood samples collected from renal transplant 
recipients (6%) gave positive results. On the other hand no samples 
out of 41blood samples (0%) collected from Haemodialysis patient 
gave positive results (Table 2).                                                           
4.3. Indirect Immunofluorescence technique (IFT) results 
51 out of 52 blood samples collected from renal transplant 
recipients (98%) gave positive results. On the other hand 25 out of 28 
blood samples (89.3%) collected from Haemodialysis patient gave 
positive results (Fig. 3&5&6).  
4.4. PCR Results (Detection of CMV DNA) 
       40 serum samples with CMV IgG including 3  tested positive for 
IgM  (samples 7, 13 and 44) and two tested negative for CMV IgG 
and IgM (18, 67  ) and three IgM equivocal serum samples (2,6,36 ) 
were selected for the  detection of  CMV DNA using the PCR. We 
detected CMV DNA in 3 out of 40 IgG positive samples (7.5%). 
CMV DNA was also detected in 2 IgM Positive out of 3 (66.6%), and 
1 of the equivocal samples (Fig.4&7).                                         
 ٤٨
4.5. Comparison between the four techniques for the diagnosis of        
CMV                                                                                                
 Table 3 compares the results of IgG and IgM ELISA, IFT and PCR 
for the diagnosis of CMV infection. 
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Table 1: Detection of CMV IgG Antibody in Kidney Patient’s 
Groups in Khartoum State by ELISA 
 
No. of % 
negative  
No. of % 
positive  
No. of 
negative  
No. of 
positive  
No. of 
screened  Group tested  
2  98  1  51  52  Renal transplant  
5  95  2  39  41  Haemodialysis patient  
3  97  3  90  93  Total  
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Table 2: Detection of CMV IgM Antibody in Kidney Patient's 
Groups in Khartoum State by ELISA 
 
No. of % 
negative  
No. of % 
positive  
No. of 
negative  
No. of 
positive  
No. of 
screened  Group tested  
94  6  49  3  52  Renal transplant  
100  0  41  0  41  Haemodialysis patient  
97  3  90  3  93  Total  
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Fig. ٣: Detection of CMV IgG Antibody in Kidney Patient's    
Groups in Khartoum State by IFT  
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Fig.4: Detection of CMV genome in Kidney Patient's Groups in 
Khartoum State by PCR      
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Table 3: Comparison between ELISA IgM, ELISA IgG, IFT and 
PCR for diagnosis CMV. 
 
PCR IFT  ELISA IgM 
ELISA 
IgG 
 
40 80 93 93 No. of tested sera
3 (7.5%) 76 (95%) 3 (3%) 90 (97%) No. of positive sera (%)
37 (92.5) 4 (5%) 90 (97%) 3 (3%) No. of Negative sera (%)
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Fig. 5: Detection of HCMV IgG Antibodies by indirect immuno-
fluorescence (Positive result) 
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Fig. 6: Detection of HCMV IgG Antibodies by indirect immuno- 
flurescence (Negative result)  
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Fig. 7: Ethidium bromide stained agareose gel (2%) 
electrophoresis of HCMV PCR products with a band of 
expected size 500 bp, carried out on DNA samples 
extracted from serum, Lane M:100 bp Ladder, (Arrow 
shows 500 bp band), Lane, 4 positive control, Lane, 3 
negative control, Lane,1-2-5-6-7 serum samples. 
 
 
 
 
 
 
 
 
 
 
500 bp 
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CHAPTER FIVE 
 
DISCUSSION 
 
Cytomegalovirus infection remains a major cause of morbidity 
and mortality in immunocomparamised patients, and most serious 
problem in organ allograft recipients. The possibility of using specific 
antiviral therapy to treat CMV infection makes a timely diagnosis 
imperative (Peterson et al 1980).  
This study was focused on the molecular and serologic 
diagnosis of human CMV in renal transplant patients and 
haemodilysis patients in Khartoum state. A number of 100 serum 
samples were collected from these two groups. 
We studied the prevalence of CMV antibodies among renal 
transplant and haemodialysis patients in Khartoum state by using 
ELISA. We found that the IgG antibody prevalence was 98% and 95% 
in renal transplant and haemodialysis patients, respectively, 
suggesting high incidence of previous infection in all groups tested. 
Eldowma (2004) was the first to detect IgG antibodies of CMV among 
blood donors and antenatal women in Sudan with 77% and 95%, 
respectively. Bushra (2006) detected 96% seropositivity for IgG in 
pretransplant kidney recipient, 17% in healthy candidate donors, and 
84% in blood donors. Since no vaccination program is practiced 
against CMV in Sudan our results denotes for previous infections with 
the virus. Taken together, our results and the findings of Eldowma 
(2004) and Bushra (2006) it is obvious that CMV is endemic in the 
Sudan. The present high CMV seroprevalence in the two groups 
studied point of high spread of the infection in the population as a 
whole. This high prevalence of CMV may be attributed to the poor 
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socioeconomic status and hygienic practice known to play an 
important role in transmission of CMV due to over-crowdness. 
According to Jawetz et al (2004) the prevalence of infection varies 
with socioeconomic status, living condition, and hygienic practices, 
antibody prevalence may be moderate (40-70%) in  adults in high 
socioeconomic group in developed countries in contrast to prevalence 
of 90% in children and adults in developing nations and in low 
socioeconomic group in develop countries. Further studies are needed 
to determine the exact prevalence of CMV infection in the different 
parts of the Sudan. 
The prevalence of CMV IgG antibodies when the same sera 
were tested by IFT was 98% and 89% in renal transplant and 
haemodialysis patients, respectively. Though the ELISA detected one 
more positive sample that was negative by IFT, our results indicate 
that IFT has a comparable sensitivity. The IFT, we used, is also a 
quantitative test that estimate level of IgG by the intensity of 
fluorescence on infected cells. The number of cells that show 
fluorescence and intensity of the colour in the cells may vary 
depending on the concentration of CMV antibodies. Thus the 
quantitative natures of the IFT help to diagnosis and monitor the 
treatment. This is the first time to introduce this technique in the 
Sudan. The routine technique that is commonly used in the diagnosis 
of the CMV in Sudan is ELISA. The sensitivity of IFT in comparison 
to ELISA observed in the present study encourage the use of this test 
in Sudan particularly because of its lowest cost. 
Furthermore, IgM ELISA was used to establish whether or not 
infection in the normal host has occurred recently. The prevalence of 
HCMV IgM, in the present study, was 6 % in renal transplant and 0 % 
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in haemodialysis. These might reflect an alarming picture of the 
disease in the population and indicate that seroconversion is an 
ongoning process in renal transplant group in the Sudan. 
The presence of HCMV IgM antibodies probably indicate 
active infection as has been reported previously by Farrell et al 
(1999). ELISA can detect HCMV antibodies of both primary CMV 
and reactivation of latent infection. Accordingly, high titer of CMV 
IgM antibodies by ELISA suggests recent exposure or reactivation of 
latent infection.  
The indirect ELISA shows the following potential sources of 
error when performed on whole serum: (i) competitive inhibition due 
to the presence of specific IgG; (ii) interference due to rheumatoid 
factor of the IgM class (IgMRF) or to IgM-RF reactive only with 
autologous complexed IgG; and (iii) interference due to IgM antibody 
reactive with cellular antigens (Champsaur et al., 1988). 
The classical methods for diagnosis HCMV have disadvantages 
like lacking of the ability to detect low level of the HCMV in samples. 
The PCR method is considered a valuble tool for diagnosis in 
Virology due to a high sensitivity that allows detection of very low a 
mounts of DNA in clinical samples (Pellegrin et al 1999). 
In the present study we detected HCMV DNA by PCR in 3 
samples out of 40 samples (7.5%) positive HCMV IgG by ELISA and 
in 2 IgM positive and in one equivocal by ELISA test. To our 
knowledge, this is the first study in Sudan to use PCR to detect CMV 
infection in renal transplant patients.  
Diagnosis of CMV by PCR is rapid, sensitive and specific when 
performed on DNA extracted from infected leucocytes. This has been 
applied to various groups of immunocompromised patients for 
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examples renal transplant, bone marrow transplant, leukemia, and 
lymphoma (Xu, 1993). The use of PCR for diagnosis of HCMV was 
established by Costa et al (1999); Bavil et al (2003); Weinberg and Li 
(1999) and Cunningham et al (2005). 
              The disadvantage with this technique is that it may detect 
latent CMV DNA in seropostive patient in the absence of clinical 
disease. In 19 of 20 immunocompromised patients leucocytes were 
positive by PCR up to 16 week after the culture become negative 
(Rathamohan et al 1993). Lower detection rate was reported by 
Krajden et al (1996) who detected HCMV DNA 8 of the 106 samples 
using ISO extraction method and 0 of the 114 samples when using the 
QIA extraction method and 1of the 113 samples when using Amplicor 
method.           The Serum has a number of advantages for detection of 
virus using PCR. It is one of the commonest specimens sent to the lab; 
it requires very little preparation befor DNA extraction and 
retrospective banks of serum samples are readily available for 
validation of the test in different patient groups.                                                           
In this study we found that there is good evidence that the same 
individuals with HCMV infection as detected by PCR gave equivocal 
result by ELISA in the serum.  
In our studies, renal transplant recipients showed CMV DNA as 
detected in serum. As a consequence, levels of CMV DNA as detected 
by PCR are highly dependent on the level of the virus DNA in the 
serum. Further studies with different kind of samples other than serum 
are needed to confirm this finding. PCR detection of CMV in serum is 
sensitive, specific and is an early indicator of both primary and 
reactivation case. When we compared the PCR with IgM ELISA we 
found that the PCR is sensitive and specific. It is also suggested that 
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any serum that test positive or equivocal by ELISA should be re-tested 
by PCR.    
The PCR is increasingly used for the diagnosis of human and 
animal diseases in Sudan; the present study established the diagnosis 
of HCMV by PCR technique in the Sudan. 
The utilization of techniques such as PCR that permit the rapid 
diagnosis of CMV infection improves the chances for implementation 
of specific antiviral treatment.  
PCR test is however relatively more expensive than the 
serologic test; this high cost is not affordable to most patients in 
Sudan at present. However PCR is needed according to our results to 
confirm active infection detected by IgM ELISA or even to replace 
this test. Effort should be continued to reduce the cost for performing 
the PCR test in Sudan through the standardization of the test and the 
use of locally prepared reagents. 
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CONCLUSION 
1. The prevalence of CMV IgG antibodies is higher in the two 
groups: renal transplant patients and haemodialysis patients. 
2.  High prevalence of HCMV IgG was found in the renal 
transplant patients and haemodialysis patients and probably the 
dialysis machince of dialysis have a role in the transmission of 
the virus. 
3. The prevalence of CMV IgM antibodies is higher in the renal 
transplant group maybe due to reactivation or new infection. 
4. By ELISA technique we can be able to detect the prevalence of 
the HCMV IgG and IgM antibodies in renal transplant patients 
and haemodialysis patients. 
5. The comparative results between ELISA (97%) and IFT (95%) 
for detection HCMV IgG antibodies. Therefore, both assays 
were sensitive and specific for detection of CMV IgG 
antibodies.  
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RECOMMENDATIONS 
1. Improving and optimization of the PCR technique and consider 
use as a routine technique in the diagnosis of HCMV in Sudan. 
2. Further research work should be carried out to molecular 
characterizion of HCMV in Sudan. 
3. PCR technique must be carried out from the peripheral blood 
leucocytes or plasma because the virus generally latent in 
peripheral blood leucocytes. 
4. All organ and blood donors should be screened for CMV 
infection prior donation. 
5. CMV positive patients should be prohibited from donating 
kidney for transfused. 
6. Individuals for haemodialysis need to be screened for CMV 
infection and those proved to be positive dialyzed on separate 
haemodialysis machine. 
7. All transplant patients should be screened for CMV infection 
periodically. 
8. Further research work should be carried out to further study the 
prevalence of CMV in other groups. The Rick associated with 
and factors predisposing to CMV infection. 
9. The role of CMV infection in renal transplant should be kept in 
consideration; therefore in every attempt for kidney 
transplantation patients should be screened for CMV antibodies 
and treated before transplantation. 
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Appendix 
1. Preparation of protinase K (20mg/ml): 
100 gm of   protinase K was added to 5ml distill water. 
2. Preparation of material for gel electrophoresis: 
2.1 Agarose 2%: 
0.5 gm of agarose (promega) was dissolved in 25 ml 1x TBE 
buffer heated in microwave for 1 min, left to cool and 0.7 µl of 
ethidium bromide was added and then poured onto electrophoresis 
Tank. 
 2.2 TBE buffer 5x (Tris-boric - EDTA): 
Boric acid                         14g 
EDTA                               0.939g      PH   8.3 
Tris base                          27.5g 
Complete in 250 ml distilled water. 
2.3 Lodding Daye: 
 Bromophenol Blue              11% 
 Glycerol                              40 µl 
 DDW                                  50 µl  
2.4 100 bp Ladder (VIVANTIS): 
Ladder (0.1 µg/ µl)               1 µl  
Blue dye                               4 µl  
2.5 Eithidium bromide: 
Stock solution (CINAGENE) 10 mg/ml  
And protected from light.                                              
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3.  Detection of CMV IgG & IgM Antibodies by ELISA and 
IFT and Virus genome by PCR in Sera Collected from 
Kidney Patients in Khartoum State, Sudan                                 
  
Tested Groups  PCR    IFT      ELISA 
IgM 
Test 
ELISA 
IgG 
Test 
Samples 
No
  
Renal transplant –  + –  +  1  
Renal transplant – + ±  +  2  
Renal transplant ND + –  +  3  
Renal transplant – + –  +  4  
Renal transplant ND  + –  +  5  
Renal transplant +  + ±  +  6  
Renal transplant –  + +  +  7  
Renal transplant –  + –  +  8  
Renal transplant ND  + –  +  9  
Renal transplant ND  + –  +  10  
Renal transplant –  + –  +  11  
Renal transplant –  + –  +  12  
Renal transplant +  + +  +  13  
Renal transplant – + –  +  14  
Renal transplant – + –  +  15  
Renal transplant ND  + –  +  16  
Renal transplantND  + –  +  17  
Renal transplant–  – –  –  18  
Renal transplant–  + –  +  19  
Renal transplantND  + –  +  20  
Renal transplant–  + –  +  21  
Renal transplant–  + –  +  22  
Renal transplant–  + –  +  23  
Renal transplant–  + –  +  24  
Renal transplant–  + –  +  25  
Renal transplantND  + –  +  26  
Renal transplantND  – –  +  27  
Renal transplantND  + –  +  28  
Renal transplantND + –  +  29  
Renal transplantND + –  +  30  
Renal transplant– + –  +  31  
Renal transplant– + –  +  32  
Renal transplantND + –  +  33  
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Renal transplant– + –  +  34  
Renal transplant– + –  +  35  
Renal transplant–  + ±  +  36  
Renal transplant–  + –  +  37  
Renal transplant–  + –  +  38  
Renal transplant –  + –  +  39  
Renal transplant ND + –  +  40  
Renal transplant ND + –  +  41  
Renal transplant –  + –  +  42  
Renal transplant ND  + –  +  43  
Renal transplant +  + +  +  44  
Renal transplant ND + –  +  45  
Renal transplant ND + –  +  46  
Renal transplant –  + –  +  47  
Renal transplant ND + –  +  48  
Renal transplant ND + –  +  49  
Renal transplant ND + –  +  50  
Renal transplant ND + –  +  51  
Renal transplant –  + –  +  52  
Haemodialysispatient –  + –  +  53  
Haemodialysis patient ND + –  +  54  
Haemodialysis patient ND + –  +  55  
Haemodialysis patient ND  + –  +  56  
Haemodialysis patient –  + –  +  57  
Haemodialysis patient ND  + –  +  58  
Haemodialysis patient ND  + –  +  59  
Haemodialysis patient ND  + –  +  60  
Haemodialysis patient –  – –  +  61  
Haemodialysis patient ND + –  +  62  
Haemodialysis patient ND + –  +  63  
Haemodialysis patient ND + –  +  64  
Haemodialysis patient ND + –  +  65  
Haemodialysis patient ND + –  +  66  
Haemodialysis patient –  – –  –  67  
Haemodialysis patient –  + –  +  68  
Haemodialysis patient ND + –  +  69  
Haemodialysis patient ND ND  –  +  70  
Haemodialysis patient ND  +  –  +  71  
Haemodialysis patient ND  ND  –  +  72  
Haemodialysis patientND  +  –  +  73  
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Haemodialysis patientND  ND  –  +  74  
Haemodialysis patientND  +  –  +  75  
Haemodialysis patientND  ND –  +  76  
Haemodialysis patient–  ND –  +  77  
Haemodialysis patientND  ND –  +  78  
Haemodialysis patient–  +  –  +  79  
Haemodialysis patient–  ND –  +  80  
Haemodialysis patientND ND –  +  81  
Haemodialysis patientND ND –  +  82  
Haemodialysis patientND ND  –  +  83  
Haemodialysis patientND ND –  +  84  
Haemodialysis patientND ND –  +  85  
Haemodialysis patientND ND –  +  86  
Haemodialysis patient–  +  –  +  87  
Haemodialysis patientND +  –  + 88 
Haemodialysis patientND +  –  +  89  
Haemodialysis patient–  +  –  +  90  
Haemodialysis patientND +  –  +  91  
Haemodialysis patientND +  –  +  92  
Haemodialysis patientND –  –  –  93  
 
+      Positive  
-       Negative  
±      Equivocal 
ND   Not done  
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Appendex.4: ELISA Microtiter plate Showing CMV IgG positive and 
Negative Serum samples. Well in column 1 row A: negative 
control, Well in column 1 row B and C: low positive and high 
positive controls, respectively.  
 
 
 
 
